Observational Study in CLL Patients Receiving BR

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to provide additional data to confirm the safety profile and efficacy of bendamustine and rituximab (BR) chemotherapy for chronic lymphocytic leukemia patients with significant comorbidities treated in routine clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Czech CLL Study Group
• Treatments: Bendamustine Hydrochloride; Rituximab

Criteria

Inclusion Criteria:

• Confirmed diagnosis of chronic lymphocytic leukemia

• Patients treated with first-line BR for active disease requiring treatment

• Cumulative Illness Rating Scale (CIRS) > 6

• Informed consent to data collection

Exclusion Criteria:

• Patients treated with BR within prospective clinical trials